Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy.

Publisher: Wiley Country of Publication: Egypt NLM ID: 101627166 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-7156 (Electronic) Linking ISSN: 23147156 NLM ISO Abbreviation: J Immunol Res Subsets: MEDLINE

Publication: 2024- : [Hoboken, NJ] : Wiley
Original Publication: Cairo, Egypt : Hindawi Publishing Corporation, [2014]-

Cancer Vaccines/*immunology ; Dendritic Cells/*immunology ; Immunotherapy, Adoptive/*methods ; Melanoma/*therapy ; Skin Neoplasms/*therapy; Alarmins/immunology ; Antigens, Neoplasm/immunology ; Dendritic Cells/transplantation ; Heat-Shock Proteins/immunology ; Hemoglobins/metabolism ; Isoantigens/immunology ; Melanoma/immunology ; Skin Neoplasms/immunology ; Cell Extracts ; Cell Line, Tumor ; Hot Temperature ; Humans ; Immunization ; Neoplasm Staging ; Proteomics

Autologous dendritic cells (DCs) loaded with cancer cell-derived lysates have become a promising tool in cancer immunotherapy. During the last decade, we demonstrated that vaccination of advanced melanoma patients with autologous tumor antigen presenting cells (TAPCells) loaded with an allogeneic heat shock- (HS-) conditioned melanoma cell-derived lysate (called TRIMEL) is able to induce an antitumor immune response associated with a prolonged patient survival. TRIMEL provides not only a broad spectrum of potential melanoma-associated antigens but also danger signals that are crucial in the induction of a committed mature DC phenotype. However, potential changes induced by heat conditioning on the proteome of TRIMEL are still unknown. The identification of newly or differentially expressed proteins under defined stress conditions is relevant for understanding the lysate immunogenicity. Here, we characterized the proteomic profile of TRIMEL in response to HS treatment. A quantitative label-free proteome analysis of over 2800 proteins was performed, with 91 proteins that were found to be regulated by HS treatment: 18 proteins were overexpressed and 73 underexpressed. Additionally, 32 proteins were only identified in the HS-treated TRIMEL and 26 in non HS-conditioned samples. One protein from the overexpressed group and two proteins from the HS-exclusive group were previously described as potential damage-associated molecular patterns (DAMPs). Some of the HS-induced proteins, such as haptoglobin, could be also considered as DAMPs and candidates for further immunological analysis in the establishment of new putative danger signals with immunostimulatory functions.

Cell. 2011 Mar 4;144(5):703-18. (PMID: 21376233)
Cell. 2015 Oct 22;163(3):712-23. (PMID: 26496610)
Diabetes Metab Res Rev. 2002 Jul-Aug;18(4):305-10. (PMID: 12203945)
Immunity. 2011 Sep 23;35(3):426-40. (PMID: 21903422)
J Biol Chem. 2005 Aug 5;280(31):28675-82. (PMID: 15951572)
Cell. 2000 May 12;101(4):365-76. (PMID: 10830164)
JCI Insight. 2016;1(7):null. (PMID: 27294203)
Cell. 2014 Nov 20;159(5):1212-1226. (PMID: 25416956)
J Immunol. 2006 Feb 15;176(4):2134-41. (PMID: 16455969)
Cell Rep. 2016 May 10;15(6):1345-58. (PMID: 27134172)
Mol Cell. 2012 Feb 24;45(4):567-80. (PMID: 22365833)
J Interferon Cytokine Res. 2011 Jan;31(1):41-7. (PMID: 21142819)
Nat Rev Immunol. 2007 Oct;7(10):790-802. (PMID: 17853902)
Nat Immunol. 2004 Oct;5(10):971-4. (PMID: 15454919)
Oncotarget. 2015 May 10;6(13):11704-13. (PMID: 25868976)
EMBO J. 2003 Nov 3;22(21):5928-40. (PMID: 14592989)
Nat Chem Biol. 2010 Sep;6(9):667-73. (PMID: 20711196)
Br J Haematol. 2006 Jul;134(1):83-91. (PMID: 16803572)
Oncogene. 1999 Jun 3;18(22):3316-23. (PMID: 10362352)
FEBS Lett. 1998 May 8;427(2):188-92. (PMID: 9607309)
Cell. 2008 May 16;133(4):627-39. (PMID: 18485871)
Cell. 2012 Jun 8;149(6):1393-406. (PMID: 22658674)
Nat Rev Immunol. 2010 Dec;10(12):826-37. (PMID: 21088683)
J Biol Chem. 2009 Oct 30;284(44):30395-407. (PMID: 19740759)
J Biol Chem. 2012 Mar 16;287(12):9473-83. (PMID: 22228765)
Cesk Farm. 1968 Jan;17(1):40-1. (PMID: 5668240)
Cell. 2013 Dec 19;155(7):1581-1595. (PMID: 24360279)
FEBS J. 2009 Nov;276(21):6158-71. (PMID: 19758344)
Exp Cell Res. 2011 Apr 1;317(6):724-36. (PMID: 21223964)
J Appl Physiol (1985). 2012 May;112(9):1529-37. (PMID: 22345427)
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52. (PMID: 25352553)
J Biol Chem. 1999 May 14;274(20):14382-91. (PMID: 10318862)
Nucleic Acids Res. 2003 Jun 15;31(12 ):3166-73. (PMID: 12799444)
J Proteome Res. 2012 Aug 3;11(8):4326-37. (PMID: 22720776)
J Immunol. 2007 Jun 1;178(11):6949-57. (PMID: 17513744)
J Biol Chem. 2000 Sep 15;275(37):28583-92. (PMID: 10893231)
Front Immunol. 2015 Nov 20;6:588. (PMID: 26635802)
Mol Cell Biol. 2010 May;30(10 ):2449-59. (PMID: 20308323)
J Biol Chem. 2006 Feb 24;281(8):4949-57. (PMID: 16338935)
Blood. 2009 Nov 19;114(21):4703-12. (PMID: 19786618)
Cancer. 2012 Jun 15;118(12):3036-43. (PMID: 22006099)
J Biol Chem. 1993 Mar 25;268(9):6622-8. (PMID: 8454633)
Cancer Immunol Immunother. 2012 Nov;61(11):2067-77. (PMID: 22552381)
J Mol Biol. 2010 Jan 8;395(1):28-41. (PMID: 19883659)
EMBO J. 2006 Sep 20;25(18):4271-83. (PMID: 16946708)
Hum Genet. 2016 Aug;135(8):851-67. (PMID: 27215579)
Br J Cancer. 2004 Jul 5;91(1):129-40. (PMID: 15199385)
Oncotarget. 2017 Feb 21;8(8):13586-13599. (PMID: 28088793)
Nat Cell Biol. 2002 Apr;4(4):302-6. (PMID: 11901422)
Sci Signal. 2014 Jan 21;7(309):ra9. (PMID: 24448649)
Curr Opin Immunol. 2003 Apr;15(2):138-47. (PMID: 12633662)
Mol Cell Biol. 2001 Feb;21(4):1285-96. (PMID: 11158314)
Biochem Biophys Res Commun. 2014 Mar 21;445(4):734-8. (PMID: 24412244)
Mol Cell Biol. 2010 Apr;30(7):1814-27. (PMID: 20123966)
Immunology. 2014 Jul;142(3):396-405. (PMID: 24673602)
J Dermatol Sci. 2000 Sep;24(1):25-37. (PMID: 10960776)
Circ Res. 2003 Jun 13;92(11):1193-200. (PMID: 12750308)
Clin Exp Immunol. 2005 Dec;142(3):555-68. (PMID: 16297169)
FEBS Lett. 2008 Jul 9;582(16):2352-6. (PMID: 18539146)
Mol Cell Biochem. 2008 Feb;309(1-2):209-15. (PMID: 17978863)
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1652-7. (PMID: 23319625)
Biochem Biophys Res Commun. 2006 Mar 3;341(1):143-9. (PMID: 16412388)
J Biol Chem. 2002 May 31;277(22):19897-904. (PMID: 11889126)
Clin Cancer Res. 2011 Apr 15;17(8):2474-83. (PMID: 21292818)
Mol Cell. 2015 Apr 2;58(1):35-46. (PMID: 25728771)
J Proteomics. 2013 Dec 6;94:346-58. (PMID: 24125732)
Genes Dev. 2005 Jul 15;19(14):1662-7. (PMID: 15985610)
Nucleic Acids Res. 2002 Feb 1;30(3):823-9. (PMID: 11809897)
Biochem Biophys Res Commun. 2007 Sep 21;361(2):287-93. (PMID: 17658461)
Biochem Biophys Res Commun. 1996 Dec 13;229(2):553-8. (PMID: 8954936)
Nat Methods. 2014 May;11(5):585-92. (PMID: 24658140)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
Cell Motil Cytoskeleton. 2008 Feb;65(2):130-42. (PMID: 17987659)
PLoS Biol. 2006 Feb;4(2):e38. (PMID: 16417406)
Nat Rev Cancer. 2012 Mar 22;12(4):265-77. (PMID: 22437871)
EMBO J. 2010 Dec 15;29(24):4132-45. (PMID: 21102410)
Biomolecules. 2014 Nov 18;4(4):994-1025. (PMID: 25412285)
J Clin Invest. 2015 Nov 03;125(12):4407-20. (PMID: 26529257)
Mol Cell Proteomics. 2014 Jul;13(7):1705-23. (PMID: 24728074)
Nat Rev Immunol. 2017 Apr;17 (4):262-275. (PMID: 28287107)
FASEB J. 2009 Nov;23(11):3682-91. (PMID: 19571038)
Cancer Immunol Immunother. 2013 Apr;62(4):761-72. (PMID: 23242374)
Oncogene. 1997 Aug 18;15(8):877-85. (PMID: 9285683)
PLoS One. 2010 Aug 10;5(8):e12093. (PMID: 20711474)
PLoS Biol. 2013;11(8):e1001635. (PMID: 23976881)
Cytokine Growth Factor Rev. 2008 Feb;19(1):93-107. (PMID: 18054517)
Autophagy. 2015;11(2):200-13. (PMID: 25714619)
Biochim Biophys Acta. 2015 Jun;1849(6):743-50. (PMID: 25623890)
Proteomics. 2007 Jun;7(11):1775-85. (PMID: 17474147)
Immunogenetics. 1994;39(3):194-200. (PMID: 8276466)
Nat Cell Biol. 2016 Feb;18(2):213-24. (PMID: 26751287)
PLoS One. 2015 Jun 22;10(6):e0126564. (PMID: 26098692)
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9722-7. (PMID: 23716661)
Hum Vaccin Immunother. 2014;10(11):3261-9. (PMID: 25625929)
Skelet Muscle. 2013 Feb 15;3(1):3. (PMID: 23414517)
Antioxid Redox Signal. 2010 Feb;12(2):261-73. (PMID: 19659436)
Nat Med. 1995 Dec;1(12):1297-302. (PMID: 7489412)
Int J Cancer. 2006 Jun 1;118(11):2803-8. (PMID: 16385567)
Mol Cell. 2003 Oct;12(4):971-82. (PMID: 14580347)
Ann Thorac Surg. 2012 May;93(5):1674-80. (PMID: 22429674)
Nat Commun. 2014 Sep 09;5:4805. (PMID: 25203508)
Proteomics. 2010 Aug;10(15):2882-6. (PMID: 20517885)
Mol Cell Biol. 2006 Mar;26(5):1932-47. (PMID: 16479011)
Mol Cell. 2012 Jun 8;46(5):674-90. (PMID: 22681889)
Eur J Immunol. 2009 Apr;39(4):965-74. (PMID: 19350579)
Mol Cell. 2006 Aug;23(4):535-46. (PMID: 16916641)
Biomolecules. 2015 Jul 15;5(3):1441-66. (PMID: 26184334)
Clin Cancer Res. 2003 Aug 1;9(8):2904-11. (PMID: 12912935)
Hum Mol Genet. 1994 Aug;3(8):1317-24. (PMID: 7987308)
Hum Pathol. 2011 Mar;42(3):393-402. (PMID: 21194727)
J Clin Oncol. 2009 Feb 20;27(6):945-52. (PMID: 19139436)
Nat Methods. 2013 Apr;10(4):307-14. (PMID: 23455922)
Cell. 2015 Apr 23;161(3):647-660. (PMID: 25910212)
Ann N Y Acad Sci. 2003 Apr;987:180-7. (PMID: 12727638)
Immunity. 2009 Jul 17;31(1):158-69. (PMID: 19592276)
J Muscle Res Cell Motil. 2017 Aug;38(3-4):303-316. (PMID: 29119312)
Cell Signal. 2007 Apr;19(4):867-79. (PMID: 17196367)
Biochem Biophys Res Commun. 2006 May 19;343(4):1159-64. (PMID: 16616011)
J Biol Chem. 1996 May 24;271(21):12525-31. (PMID: 8647861)
Circ Res. 2015 May 8;116(10):1670-9. (PMID: 25801896)
J Clin Invest. 2012 Jan;122(1):383-7. (PMID: 22156194)
EMBO J. 2004 Jan 28;23(2):406-17. (PMID: 14726956)

0 (Alarmins)
0 (Antigens, Neoplasm)
0 (Cancer Vaccines)
0 (Cell Extracts)
0 (Heat-Shock Proteins)
0 (Hemoglobins)
0 (Isoantigens)

Date Created: 20180511 Date Completed: 20180910 Latest Revision: 20181114

20260130

PMC5878886

10.1155/2018/3982942

29744371